I don't expect much at this point, not much sales. But it will be interesting if they mention how many Free samples they gave out.
ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016
ACADIA to Host Conference Call and Webcast on Thursday, August 4, 2016, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Jul. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2016 on Thursday, August 4, 2016, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Thursday, August 4, 2016, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and operations.
Yahoo could have made a ton of money - they could have charged for the old message board. If reasonable I would have paid for it. They could have offered a few new features etc. I am surprised they didn't try it.
OK here is AVXL's explanation of why the data looked bad.
Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients Presented at AAIC 2016
New York, NY – July 29, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), confirms the information in the July 27, 2016 press release announcing positive results from the Phase 2a Alzheimer’s trial for ANAVEX 2-73.
Dr. Norman Relkin, MD, PhD, an Alzheimer clinical trialist and an advisor to Anavex, commented: “To interpret the ANAVEX 2-73 results presented at the 2016 AAIC meeting, it is important to keep in mind the stated goals of this first in Alzheimer’s patients study. This was a Phase 2a study, primarily designed to determine which ANAVEX 2-73 dosages are safe to administer to mild to moderate stage Alzheimer’s patients. The study was successful in establishing the maximum tolerated dose and in revealing the range of ANAVEX 2-73 doses that are well-tolerated by Alzheimer patients. It also provided encouraging evidence that previously reported positive trends in certain cognitive and biologic measures persisted over a period of approximately 31 weeks. However, this analysis was based on pooled data from a relatively small number of subjects receiving a variety of doses. It is therefore unlikely that these findings reflect the full potential ANAVEX 2-73 in treating Alzheimer’s disease. It is unreasonable to draw conclusions about any limits to the long-term efficacy of ANAVEX 2-73 based on the interim Phase 2a findings, especially since no statistically significant decline from baseline was reported, which is impressive. Detailed pre-planned analysis of the pharmacodynamic results is in progress, which is one of the key factors of relevance for regulatory agencies and which will also determine the optimal dose for future studies."
Anavex confirms that there has been no change with regards to its science, data or the fundamentals of the Company. Anavex remains
I see the data is out and it was poor at best. I hope you got out ? I have thought it was Over bought and somewhat risky for a long time. I wouldn't buy it at this point either. It is a set up to go a lot lower.
Acadia has been pulling away from the IBB for about the last 1 week. Not a major thing so far, but shows biotech investors starting to take notice.
Well BB have like 24 M shares so yeah they will be in the front seat. I am thinking MRK, JNJ or PFE. They got the Big bucks and I can't see them letting another smaller biotech grabbing ACAD on the cheap.
What are you talking about, all companies meet with analyst. SOP especially for small companies. Come on, you know that super.
Those are the words of someone from Needham, and since we don't even know what was exactly said we can't even say it's a good interpretation of what management might have said. Personally, I would doubt very much management would tell an investment company they were not enthusiastic about upcoming trial results.
But that RLYP Buy out left some Longs in the Red, Look at the chart, most likely some bought last year Over $40. Mar 2015, High was $41.71. The Buy Out price is not a new high. Just goes to show you have to be careful of your buy points. Consider what criteria you are using when you take a long position. Acadia's Buy Out price will most likely be at a NEW HIGH...I am thinking $75-85.
Also you can go to Twitter, but there so much spam and so many shorts you would have to block 80% of the posters EVERYDAY- thats how Twitter makes their money.
Type Value Conf.
resist. 47.86 1
resist. 41.55 2
resist. 39.88 2
resist. 35.97 2
resist. 33.46 16
supp 30.30 2
supp 27.18 5
supp 23.60 3
supp 21.24 5
supp 19.23 2
supp 17.32 4
Upgrade survey points
half of the respondents (55%) self-identified as early adopters, or aggressive prescribers of newly FDA approved drugs
survey suggests a LARGER PDP population than previously modeled.Data supports robust penetration into the market
half of respondents indicated they would use Nuplazid off-label.👍10% specifically indicating would use Nuplazid in Alzheimer’s ( thank you super trades on IV. )
Well first of all she's not president just yet. But she talks anti-biotech, but really at least one of those times I don't blame her when Martin Shkreli raised the price of that anti-parasite drug used in some HIV patients to $750 a pill from $13.50. I don't blame Hillary one bit. But at some point later she did come out and say...." I want to cure cancer ", meaning she would aide in the fight to cure cancer. Even if she gets elected I don't see her making a dramatic anti-biotech move. Yeah she twitts and the market temporarily drops, but will she if elected try to pass price controls of drugs - I doubt it. The back lash will be biotech escaping to the EU & UK. I don't see her making that move if elected.
All that stuff you mentioned- basically has NO relationship to Acadia's research and Nuplazid. Its already an approved product and thus it can not be rejected or get an FDA CRL, have a trial halt, re-trial, outright rejection....reverse split ...lack of financing...bankruptcy...etc will NEVER OCCUR to Acadia...Total Cash 457.24M
As far as with other atypical antipsychotic drugs, Nuplazid has a Boxed Warning alerting health care professionals about an increased risk of death associated with the use of these drugs to treat older people with dementia-related psychosis. BUT....No drug in this class is approved to treat patients with dementia-related psychosis. And of course Nuplazid is the ONLY drug indicated to treat PDP.
Poised for growth
This Could Be the Next Big Pharma Buyout
Once biotech M&A heats up again, Acadia, Bluebird, and Jazz could be the first targets on the list, according to our Motley Fool contributors. July 18, 2016
Brian Feroldi: One company that's likely to be on Big Pharma's watch list is Acadia Pharmaceuticals (NASDAQ:ACAD). Acadia recently won FDA approval for its first drug, called Nuplazid, which has been approved to treat Parkinson's disease psychosis, or PDP.
Since there aren't currently any good treatment options for PDP, Acadia should have this market all to itself. Roughly 40% of the 1 million people in the U.S. who have Parkinson's disease suffer from PDP. With a wholesale price tag of $23,400 per year, it's not hard to believe that Nuplazid could turn into a blockbuster.
So why hasn't Big Pharma moved in on Acadia yet? It's possible that the industry is waiting to see how the drug performs on the market for a few quarters. These companies might also have reservations because during Nuplazid's late-stage trials, there was an uptick in the number of deaths among patients who used the drug compared with the control group. That fact might keep some providers from recommending the drug, which could suppress demand.
My hunch is that the healthcare community will still embrace Nuplazid with open arms because PDP places a huge burden on caregivers, but only time will tell. In the meantime, I think Acadia's stock could be an interesting opportunity for any investor with a high tolerance for risk.